ACMR Insider Filing: David H. Wang Exercises Options and Sells Shares Under 10b5-1 Plan
Rhea-AI Filing Summary
ACM Research, Inc. (ACMR) reporting person David H. Wang, who is CEO, President and a director, disclosed multiple transactions on September 3-4, 2025. Mr. Wang exercised 130,000 stock options (70,000 on 09/03/2025 and 60,000 on 09/04/2025) at a $1 exercise price, each option fully vested and exercisable and underlying the same number of Class A shares.
He also sold a total of 130,000 Class A shares across those dates in several trades under a Rule 10b5-1 trading plan adopted on November 29, 2024, with weighted-average sale prices reported: $26.73 (66,057 shares), $27.31 (3,943 shares) and $26.44 (60,000 shares). After these transactions Mr. Wang reported beneficial ownership of 742,708 Class A shares directly and various indirect holdings through family trusts and relatives summing in disclosures (examples include 620,001 shares by the Wang-Chen Family Living Trust).
Positive
- Sales executed under a Rule 10b5-1 trading plan, providing an affirmative defense and procedural clarity
- Detailed disclosure of weighted-average sale prices and offer to provide per-price breakdowns on request
- Continued substantial ownership evidenced by 742,708 direct Class A shares and additional indirect holdings through family trusts
Negative
- Insider sold 130,000 shares within two days, which may be perceived negatively by some investors despite the 10b5-1 plan
- Large option exercises and concurrent sales could be viewed as monetization of equity by the CEO
Insights
TL;DR: CEO exercised vested options and sold shares under a pre-established 10b5-1 plan; ownership remains materially significant.
Mr. Wang exercised 130,000 options at $1 and sold 130,000 shares across two days under a Rule 10b5-1 plan, with weighted-average prices reported between $26.44 and $27.31. These actions are routine in nature for executives monetizing vested equity while relying on an affirmative defense plan. The filings show continued substantial direct and indirect ownership, with 742,708 Class A shares reported directly and additional indirect holdings disclosed through family trusts and relatives, indicating sustained alignment with shareholder interests. No derivative dispositions other than option exercises were reported.
TL;DR: Transactions consistent with governance best practices if trades were pre-planned; disclosure is detailed and compliant.
The Form 4 indicates the sales were effected pursuant to a Rule 10b5-1 trading plan adopted on November 29, 2024, which supports an affirmative defense against insider trading claims. The report includes weighted-average sale prices and offers to provide per-price breakdowns on request, reflecting thorough disclosure. The report is signed by an attorney-in-fact, and the officer role is disclosed. Material governance items such as intent or non-routine related-party transfers are not present in the filing.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option | 60,000 | $0.00 | -- |
| Exercise | Class A Common Stock | 60,000 | $1.00 | $60K |
| Sale | Class A Common Stock | 60,000 | $26.44 | $1.59M |
| Exercise | Stock Option | 70,000 | $0.00 | -- |
| Exercise | Class A Common Stock | 70,000 | $1.00 | $70K |
| Sale | Class A Common Stock | 66,057 | $26.73 | $1.77M |
| Sale | Class A Common Stock | 3,943 | $27.31 | $108K |
| holding | Class A Common Stock | -- | -- | -- |
| holding | Class A Common Stock | -- | -- | -- |
| holding | Class A Common Stock | -- | -- | -- |
| holding | Class A Common Stock | -- | -- | -- |
Footnotes (1)
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 29, 2024. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.25 to $27.19, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2), (3), and (4) to this Form 4. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.29 to $27.33, inclusive. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.14 to $26.68, inclusive. The option is fully vested and exercisable.
